On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...

Salt Lake City-based Recursion Pharmaceuticals is joining forces with the United Kingdom’s Exscientia, a biotechnology company that specializes in cancer research, in a $688 million deal executives ...

Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing agreement with Takeda Pharmaceutical ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...